Key facts
- Sanodyne Therapeutics’s last known valuation is $5.5M (Jun 2025).
- It has raised $1.4M; the latest was Seed Round ($1.4M) in Jun 2025.
- Notable investors include JIC Venture Growth Investments, Remiges Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sanodyne Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sanodyne Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sanodyne Therapeutics
Developer of biotech-driven pain management treatments designed to support individuals affected by peripheral neuropathy and chronic pain. The company pioneers breakthrough therapies that address the root causes of nerve damage, enabling patients to enhance well-being and improve long-term quality of life.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2025
- Website
- sanodyne.com/
- Ownership
- Privately Held (backing)
Sanodyne Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sanodyne Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sanodyne Therapeutics in its N-PORT filings yet. We sweep new filings monthly.